Extraordinary general meeting of Nuevolution AB (publ)

An extraordinary general meeting in Nuevolution AB (publ) was held on 1 July
2016.

The extraordinary general meeting resolved to amend the terms and conditions of
the company’s incentive program, warrant program 2015/2021, in accordance with
the major shareholders’ proposal. The complete proposal is included in the
notice for the general meeting available on the company’s website. The
resolution entails an amendment of the terms and conditions of warrants of
Series 1 and Series 2.

It was, inter alia, resolved to amend the terms and conditions for warrants of
Series 1 and Series 2 so that applicable so-called “exit events” also shall
include a listing on Nasdaq First North. In addition, in order for the
applicable exit event relating to warrants of Series 1 to occur, the value per
share, at the time of application for subscription of shares by exercise of
warrants, shall correspond to at least SEK 22.975. Upon fulfillment of an exit
event relating to Series 1, the subscription price per share shall be lowered to
SEK 17.50, and for Series 2, the subscription price per share shall be lowered
to SEK 11.25. As a result of the general meeting’s resolution to amend the terms
and conditions of the warrants, exit event relating to warrants of Series 2 has
been fulfilled.

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 7020 0987

Email: ahg@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its
proprietary discovery platform and programs with pharmaceutical and
biotechnology companies to seek future benefit of patients in need of novel
medical treatment options. Nuevolution’s internal programs are focused
on therapeutically important targets within inflammation, oncology and immuno
-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial Instruments Trading
Act. The information was sent for publication on Friday 1 July 2016, 13:00
(CET).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm,
Sweden (ticker: NUE). Västra Hamnen Corporate Finance AB acts as Certified
Adviser to Nuevolution AB (publ). More information about Nuevolution can be
found on: www.nuevolution.com